ParenteralTopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Dihydroergotamine Mesylate

CAS 6190-39-2

Dihydroergotamine Mesylate (CAS 6190-39-2) is a Phase 4 pharmaceutical compound with 4 bioactivity targets and 2 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Dihydroergotamine Mesylate

CAS Number

6190-39-2

UNII

81AXN7R2QT

InChIKey

ADYPXRFPBQGGAH-UMYZUSPBSA-N

ChEMBL ID

CHEMBL1200517

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

DIHYDROERGOTAMINEMigranal

black box warningdosed ingredientnatural productparenteraltherapeutic flagtopical

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1200517 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	2108.6757894736843 nM	69	-
-	Potency	11848.620833333334 nM	24	-
-	Ki	412.8875 nM	20	-
-	EC50	4558.501428571429 nM	7	-

SOURCE IUPHAR/BPS 7 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
5-HT 1D receptor HTR1D	Full agonist	9.199999809265137 pKi	9605573\|8967979\|1652050
5-HT 1B receptor HTR1B	Full agonist	8.0 pKi	8863519\|8967979
5-HT 1F receptor HTR1F	Full agonist	6.6 pKi	15900510\|9225282
5-HT 6 receptor Htr6	Antagonist	7.9 pKi	7680751\|9798944
5-HT 7 receptor Htr7	Antagonist	6.8 pKi	8397408
5-HT 7 receptor HTR7	Antagonist	8.0 pKi	8226867
5-ht 1e receptor HTR1E	Full agonist	5.6 pKi	8863519

SOURCE PharmGKB 1 phenotype row

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

HTR1B rs130060

Evidence: 3; PMID 1

SOURCE NLM RxNorm 6 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
DIHYDROERGOTAMINE	3418	SU	MTHSPL
Dihydroergotamine mesylate	203176	SU	MTHSPL
DIHYDROERGOTAMINE MESYLATE	203176	SU	MTHSPL
dihydroergotamine	3418	IN	RXNORM
Migranal	42643	BN	RXNORM
dihydroergotamine mesylate	203176	PIN	RXNORM

SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Abdominal pain	dihydroergotamine	LLT	C0000737
Abdominal pain	dihydroergotamine	PT	C0000737
Abnormal vision	dihydroergotamine	LLT	C3665386
Acute coronary syndrome	dihydroergotamine	PT	C0948089
Agitation	dihydroergotamine	PT	C0085631
Angina pectoris	dihydroergotamine	LLT	C0002962
Angina pectoris	dihydroergotamine	PT	C0002962
Anorexia	dihydroergotamine	LLT	C0003123
Anxiety	dihydroergotamine	LLT	C0003467
Anxiety	dihydroergotamine	PT	C0003467
Aphonia	dihydroergotamine	LLT	C0003564
Aphonia	dihydroergotamine	PT	C0003564
Application site reaction	dihydroergotamine	LLT	C0151505
Application site reaction	dihydroergotamine	PT	C0151505
Arteriospasm coronary	dihydroergotamine	LLT	C0010073
Arteriospasm coronary	dihydroergotamine	PT	C0010073
Arthralgia	dihydroergotamine	LLT	C0003862
Arthralgia	dihydroergotamine	PT	C0003862
Asthenia	dihydroergotamine	LLT	C0004093
Asthenia	dihydroergotamine	PT	C0004093
Asthenia	dihydroergotamine	PT	C0004093
Bladder pain	dihydroergotamine	PT	C0232849
Body temperature increased	dihydroergotamine	LLT	C0015967
Body temperature increased	dihydroergotamine	PT	C0015967
Bronchitis	dihydroergotamine	LLT	C0006277
Bronchitis	dihydroergotamine	PT	C0006277
Bronchospasm	dihydroergotamine	LLT	C0006266
Bronchospasm	dihydroergotamine	PT	C0006266
Cerebration impaired	dihydroergotamine	LLT	C0235198
Cerebrovascular accident	dihydroergotamine	LLT	C0038454
Cerebrovascular accident	dihydroergotamine	PT	C0038454
Chills	dihydroergotamine	PT	C0085593
Cold sweat	dihydroergotamine	LLT	C0232431
Cold sweat	dihydroergotamine	PT	C0232431
Cold sweat	dihydroergotamine	PT	C0232431
Confusional state	dihydroergotamine	LLT	C0009676
Confusional state	dihydroergotamine	PT	C0009676
Conjunctivitis	dihydroergotamine	LLT	C0009763
Conjunctivitis	dihydroergotamine	PT	C0009763
Cramp muscle	dihydroergotamine	LLT	C0026821
Cystitis	dihydroergotamine	LLT	C0010692
Cystitis	dihydroergotamine	PT	C0010692
Cystitis noninfective	dihydroergotamine	PT	C0403632
Decreased appetite	dihydroergotamine	PT	C0232462
Depressed level of consciousness	dihydroergotamine	PT	C0549249
Dermatitis	dihydroergotamine	PT	C0011603
Diarrhoea	dihydroergotamine	LLT	C0011991
Diarrhoea	dihydroergotamine	PT	C0011991
Discomfort	dihydroergotamine	PT	C0234215
Discomfort	dihydroergotamine	LLT	C0234215
Discomfort	dihydroergotamine	PT	C0234215
Disturbance in attention	dihydroergotamine	PT	C0233414
Dizziness	dihydroergotamine	LLT	C0012833
Dizziness	dihydroergotamine	PT	C0012833
Dry mouth	dihydroergotamine	LLT	C0043352
Dry mouth	dihydroergotamine	PT	C0043352
Dyspepsia	dihydroergotamine	LLT	C0013395
Dyspepsia	dihydroergotamine	PT	C0013395
Dysphagia	dihydroergotamine	LLT	C0011168
Dysphagia	dihydroergotamine	PT	C0011168
Dyspnoea	dihydroergotamine	LLT	C0013404
Dyspnoea	dihydroergotamine	PT	C0013404
Ear pain	dihydroergotamine	LLT	C0013456
Ear pain	dihydroergotamine	PT	C0013456
Epistaxis	dihydroergotamine	LLT	C0014591
Epistaxis	dihydroergotamine	PT	C0014591
Euphoric mood	dihydroergotamine	LLT	C0235146
Euphoric mood	dihydroergotamine	PT	C0235146
Eye pain	dihydroergotamine	LLT	C0151827
Eye pain	dihydroergotamine	PT	C0151827
Face oedema	dihydroergotamine	LLT	C0542571
Face oedema	dihydroergotamine	PT	C0542571
Fatigue	dihydroergotamine	LLT	C0015672
Fatigue	dihydroergotamine	PT	C0015672
Feeling abnormal	dihydroergotamine	PT	C1443060
Feeling abnormal	dihydroergotamine	PT	C1443060
Flushing	dihydroergotamine	LLT	C0016382
Flushing	dihydroergotamine	PT	C0016382
Gait disturbance	dihydroergotamine	LLT	C0575081
Gait disturbance	dihydroergotamine	PT	C0575081

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Dihydroergotamine Mesylate used for in pharmaceutical contexts?

Dihydroergotamine Mesylate (CAS 6190-39-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Dihydroergotamine Mesylate?

Dihydroergotamine Mesylate has 2 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pulmonary embolism. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Dihydroergotamine Mesylate also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Dihydroergotamine with EU status "prohibited".

What clinical phase is Dihydroergotamine Mesylate in?

Dihydroergotamine Mesylate is rendered with ChEMBL max phase 4 (approved).